Compare BOKF & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOKF | HALO |
|---|---|---|
| Founded | 1910 | 1998 |
| Country | United States | United States |
| Employees | 5034 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 8.8B |
| IPO Year | 2007 | 2001 |
| Metric | BOKF | HALO |
|---|---|---|
| Price | $126.46 | $67.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $127.10 | $78.18 |
| AVG Volume (30 Days) | 292.4K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 12.65 | N/A |
| EPS | ★ 9.17 | 2.56 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $6.56 | $28.24 |
| Revenue Next Year | $5.35 | $12.79 |
| P/E Ratio | ★ $13.67 | $26.28 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $85.08 | $47.50 |
| 52 Week High | $138.42 | $82.22 |
| Indicator | BOKF | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 40.54 | 37.52 |
| Support Level | $103.22 | $63.85 |
| Resistance Level | $138.25 | $68.00 |
| Average True Range (ATR) | 3.53 | 1.94 |
| MACD | -0.87 | -0.58 |
| Stochastic Oscillator | 34.73 | 21.55 |
BOK Financial Corp is a financial institution based in Oklahoma that offers a broad range of nationally competitive financial products and services. The company operates through three main segments: Commercial Banking, Consumer Banking, and Wealth Management. Commercial Banking provides lending, treasury and cash management, and risk management services, and includes the TransFund EFT network. Consumer Banking focuses on retail lending, deposit services, and mortgage loan origination and servicing. Wealth Management engages mainly in brokerage and trading activities, particularly in U.S. government agency mortgage-backed securities and related derivatives. The company generates the majority of its revenue from the Commercial Banking segment.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.